PARP1

Across TCGA pan-cancer cohorts, PARP1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PARP1 data layer compared with 24 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PARP1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PARP1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

HNSC, CCRCC, and PDAC are the cancer types where PARP1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.747	0.919	<.001	91	view →
CCRCC	OS	Median	All	0.891	1.000	.004	12	view →
PDAC	DFS	Median	All	0.828	0.697	.001	12	view →
LUAD	OS	Median	All	0.918	0.771	.018	11	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PARP1–HNSC (OS)

Open the HNSC breakdown →